PTCT

NEUTRAL

$72.43 Live

PTC Therapeutics, Inc. · NASDAQ

Target $87.87 (+21.3%)

$35.95 52W Range $87.5

PTCT PTC Therapeutics, Inc. - Fundamental Analysis

NEUTRAL

Console Chart News

PTCT Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$72.43

Analyst Target

$87.87

+21.3% Upside

52W High

$87.5

52W Low

$35.95

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$6.0B

P/E

8.44

ROE

N/A

Profit margin

39.4%

Debt/Equity

N/A

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

80%

PTCT presents a paradoxical profile: it boasts a perfect Piotroski F-Score of 9/9, indicating strong short-term financial improvement, yet suffers from negative revenue growth (-22.70%) and heavy insider selling. While the current P/E of 8.44 appears attractive, the jump to a Forward P/E of 29.81 suggests a significant expected decline in earnings. The stock is currently trading at a premium to its growth-based intrinsic value of $60.06, though analyst targets remain optimistic at $87.87. Overall, the strong balance sheet liquidity (Current Ratio 2.35) offsets the operational volatility, but the lack of growth and insider confidence warrants a neutral stance.

Key Strengths

Perfect Piotroski F-Score (9/9) indicating strong fundamental health trends

High Gross Margin (70.98%) reflecting strong pricing power or low COGS

Strong liquidity position with a Current Ratio of 2.35

Positive 1-year price performance (+52.8%)

Strong analyst support with a 'Buy' consensus and target price of $87.87

Key Risks

Significant negative revenue growth (-22.70% YoY and Q/Q)

Heavy insider selling (16 transactions, 0 buys) including CEO and COO

Extreme earnings volatility with massive surprise swings (e.g., -1097.5% recent surprise)

Negative Book Value (P/B -28.74) indicating accumulated deficits

Bearish technical trend (0/100) despite long-term gains

AI Fair Value Estimate

Based on comprehensive analysis

$62.5

-13.7% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Hold

Key drivers: Piotroski F-Score, Revenue Decline, Insider Selling, Earnings Volatility

Confidence

85%

Value

45/100

Trades at a premium to intrinsic value; trailing P/E is likely skewed by one-time gains.

Positives

Low trailing P/E (8.44)

Watchpoints

Price ($72.43) exceeds Intrinsic Value ($60.06)
High Forward P/E (29.81)
Negative Price/Book

Future

30/100

Growth metrics are currently negative, contradicting the 'Buy' analyst sentiment.

Positives

Analyst target price suggests 21% upside

Watchpoints

Negative YoY and Q/Q revenue growth
Declining earnings trajectory

Past

60/100

Price performance has been strong, but fundamental earnings have been erratic.

Positives

Strong 1Y and 3Y price appreciation

Watchpoints

Highly inconsistent earnings track record

Health

90/100

Exceptional short-term financial health scores despite long-term equity deficits.

Positives

Piotroski F-Score 9/9
Current Ratio 2.35
Quick Ratio 2.20

Watchpoints

Negative equity (Price/Book)

Dividend

0/100

Typical for biotech; 0/100 dividend strength.

Positives

No standout positives identified.

Watchpoints

No dividend payments

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$72.43

Analyst Target

$87.87

Upside/Downside

+21.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PTCT and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
PTCT PTC Therapeutics, Inc. Primary	+52.4%	+36.8%	+52.8%	+9.8%	+8.1%	+5.4%
BLCO Bausch + Lomb Corporation Peer	-15.1%	-0.2%	+0.8%	+18.6%	-0.2%	-1.1%
MIRM Mirum Pharmaceuticals, Inc. Peer	+417.6%	+286.1%	+143.7%	+33.7%	+6.4%	+0.3%
RGEN Repligen Corporation Peer	-39.7%	-30.0%	-7.4%	-11.9%	-5.7%	+1.3%
HQY HealthEquity, Inc. Peer	+11.9%	+34.2%	-2.5%	-13.9%	-0.8%	-7.9%

PTC

PTC Therapeutics, Inc.

Primary

+52.4%

+36.8%

+52.8%

+9.8%

+8.1%

+5.4%

BLC

Bausch + Lomb Corporation

Peer

-15.1%

-0.2%

+0.8%

+18.6%

-0.2%

-1.1%

MIR

Mirum Pharmaceuticals, Inc.

Peer

+417.6%

+286.1%

+143.7%

+33.7%

+6.4%

+0.3%

RGE

Repligen Corporation

Peer

-39.7%

-30.0%

-7.4%

-11.9%

-5.7%

+1.3%

HQY

HealthEquity, Inc.

Peer

+11.9%

+34.2%

-2.5%

-13.9%

-0.8%

-7.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

8.44

29.81

N/A

-28.74

3.46

3.9

7.55

$6.0B

Profitability

Profit margins and return metrics

Profit Margin 39.44%

Operating Margin -49.57%

Gross Margin 70.98%

ROE N/A

ROA 23.26%

Growth

Revenue and earnings growth rates

Revenue Growth -22.7%

Earnings Growth N/A

Q/Q Revenue Growth -22.75%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

N/A

Current Ratio

2.35

Strong

Quick Ratio

2.2

Excellent

Cash/Share

$23.5

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.2B

Gross Margin

95.8%

Op. Margin

-49.6%

Net Margin

-82.0%

Total Assets

$2.9B

Liabilities

$3.1B

Equity

$-0.2B

Debt/Equity

-15.12x

Operating CF

$-0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.1B

FCF Yield

209%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07

$N/A

2026-02-19

$-1.8

-1097.5% surprise

2025-11-04

$0.2

+114.6% surprise

2025-08-07

$-0.83

+21.9% surprise

Healthcare Sector Comparison

Comparing PTCT against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)

P/E Ratio

8.44

This Stock

89.02

Sector Avg

-90.5% (Discount)

Profit Margin

39.44%

This Stock

-13.63%

Sector Avg

-389.4% (Weaker)

Revenue Growth

-22.7%

This Stock

121.05%

Sector Avg

-118.8% (Slower)

Current Ratio

2.35

This Stock

4.55

Sector Avg

-48.4% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
PTCT PTC Therapeutics, Inc.	NEUTRAL	$6.0B	8.44	-%	39.4%	$72.43
BLCO Bausch + Lomb Corporation	BEARISH	$6.01B	-	-4.5%	-6.1%	$16.98	Compare
MIRM Mirum Pharmaceuticals, Inc.	BEARISH	$5.82B	-	-8.6%	-4.5%	$96.49	Compare
RGEN Repligen Corporation	NEUTRAL	$6.64B	137.0	2.4%	6.6%	$117.82	Compare
HQY HealthEquity, Inc.	NEUTRAL	$6.66B	31.69	10.2%	16.4%	$77.96	Compare

PTCT PTC Therapeutics, Inc.

NEUTRAL

Mkt Cap

$6.0B

P/E

8.4

ROE

Price

$72.43

BLCO Bausch + Lomb...

Compare with PTCT

Compare with PTCT

RGEN Repligen Corporation

Compare with PTCT

HQY HealthEquity, Inc.

Compare with PTCT

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-04-06	BOULDING MARK ELLIOTT	Officer	Sale	2,265	$157,293
2026-04-06	BOULDING MARK ELLIOTT	Officer	Option Exercise	2,265	$89,286
2026-04-02	GOLDEN LEE SCOTT	Officer	Sale	829	$56,364
2026-04-01	ALMSTEAD NEIL GREGORY	Chief Operating Officer	Sale	52,003	$3,590,243
2026-03-24	CHUTTER JESSICA CAROLINE	Director	Stock Award	7,333	-
2026-03-12	KLEIN MATTHEW B	Chief Executive Officer	Sale	2,662	$170,581
2026-03-11	KLEIN MATTHEW B	Chief Executive Officer	Stock Award	12,500	-
2026-03-10	OKEY STEPHANIE S	Director	Sale	15,167	$1,061,690
2026-03-10	OKEY STEPHANIE S	Director	Option Exercise	15,167	$510,066
2026-03-05	GOLDEN LEE SCOTT	Officer	Sale	10,000	$633,800
2026-03-05	OKEY STEPHANIE S	Director	Sale	6,333	$401,386
2026-03-05	ALMSTEAD NEIL GREGORY	Chief Technology Officer	Sale	3,989	$252,823
2026-02-19	BOULDING MARK ELLIOTT	Officer	Sale	3,019	$209,763
2026-02-18	GOLDEN LEE SCOTT	Officer	Sale	2,484	$172,290
2026-02-18	UTTER CHRISTINE MARIE	Officer	Sale	2,494	$172,984

BOULDING MARK ELLIOTT

Officer

Sell

2026-04-06

2,265 shares · $157,293

BOULDING MARK ELLIOTT

Officer

Option Exercise

2026-04-06

2,265 shares · $89,286

GOLDEN LEE SCOTT

Officer

Sell

2026-04-02

829 shares · $56,364

ALMSTEAD NEIL GREGORY

Chief Operating Officer

Sell

2026-04-01

52,003 shares · $3,590,243

CHUTTER JESSICA CAROLINE

Director

Stock Award

2026-03-24

7,333 shares

KLEIN MATTHEW B

Chief Executive Officer

Sell

2026-03-12

2,662 shares · $170,581

KLEIN MATTHEW B

Chief Executive Officer

Stock Award

2026-03-11

12,500 shares

OKEY STEPHANIE S

Director

Sell

2026-03-10

15,167 shares · $1,061,690

OKEY STEPHANIE S

Director

Option Exercise

2026-03-10

15,167 shares · $510,066

GOLDEN LEE SCOTT

Officer

Sell

2026-03-05

10,000 shares · $633,800

OKEY STEPHANIE S

Director

Sell

2026-03-05

6,333 shares · $401,386

ALMSTEAD NEIL GREGORY

Chief Technology Officer

Sell

2026-03-05

3,989 shares · $252,823

BOULDING MARK ELLIOTT

Officer

Sell

2026-02-19

3,019 shares · $209,763

GOLDEN LEE SCOTT

Officer

Sell

2026-02-18

2,484 shares · $172,290

UTTER CHRISTINE MARIE

Officer

Sell

2026-02-18

2,494 shares · $172,984

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

2026-03-25

PTCT filed an 8-K on March 25, 2026, likely to announce its annual financial results.

10-K

2026-02-19

PTCT filed its annual 10-K report on February 19, 2026. No specific financial highlights or risk factors were provided in the available excerpts for analysis.

8-K

2026-02-19

PTCT filed an 8-K on February 19, 2026, likely to announce its annual financial results for the fiscal year ended December 31, 2025.

8-K

2026-02-12

PTCT filed an 8-K on February 12, 2026, likely to announce its annual or quarterly financial results.

8-K

2026-01-12

8-K

2025-12-29

10-Q

2025-11-04

PTCT filed its 10-Q on November 4, 2025. Due to the limited content provided in the excerpts, specific financial highlights and detailed risk factors are unavailable for summary.

8-K

2025-11-04

PTCT filed an 8-K on November 4, 2025, likely to report its third-quarter financial results.

8-K

2025-08-19

PTCT filed an 8-K on August 19, 2025, likely to announce its second-quarter financial results.

8-K

2025-08-07

PTCT filed an 8-K on August 7, 2025, likely to announce its second-quarter financial results.

8-K

2025-08-07

10-Q

2025-08-07

8-K

2025-07-28

8-K

2025-06-17

8-K

2025-05-06

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

15 analysts

Jefferies

2026-03-30

down

Buy Hold

Morgan Stanley

2026-02-23

Maintains

Overweight Overweight

Wells Fargo

2026-02-20

Maintains

Overweight Overweight

RBC Capital

2026-02-20

Maintains

Sector Perform Sector Perform

B of A Securities

2026-02-20

Maintains

Buy Buy

Barclays

2026-01-28

Equal-Weight Overweight

RBC Capital

2025-12-01

down

Outperform Sector Perform

Barclays

2025-11-06

Maintains

Equal-Weight Equal-Weight

Citigroup

2025-11-05

Maintains

Neutral Neutral

TD Cowen

2025-11-05

Maintains

Hold Hold

Past News Coverage

Recent headlines mentioning PTCT from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

PTCT

PTCT PTC Therapeutics, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!